Truist Financial Cuts Perspective Therapeutics (NYSE:CATX) Price Target to $10.00

Perspective Therapeutics (NYSE:CATX) had its price target cut by Truist Financial from $21.00 to $10.00 in a report issued on Monday,Benzinga reports. They currently have a buy rating on the stock.

CATX has been the topic of a number of other reports. Wedbush reissued an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research note on Wednesday, March 26th. Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Perspective Therapeutics in a research report on Monday, March 31st. Scotiabank began coverage on Perspective Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price target on the stock. Finally, Royal Bank of Canada dropped their target price on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a report on Thursday, March 27th. One analyst has rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Perspective Therapeutics presently has an average rating of “Buy” and a consensus price target of $12.75.

Perspective Therapeutics Trading Up 11.1 %

Shares of CATX stock opened at $1.90 on Monday. The business’s 50 day moving average is $2.58 and its two-hundred day moving average is $5.57. Perspective Therapeutics has a 12-month low of $1.60 and a 12-month high of $19.05.

Insider Transactions at Perspective Therapeutics

In related news, Director Robert F. Williamson III acquired 38,145 shares of the company’s stock in a transaction dated Monday, March 31st. The stock was bought at an average price of $2.14 per share, with a total value of $81,630.30. Following the purchase, the director now directly owns 108,982 shares in the company, valued at $233,221.48. The trade was a 53.85 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Johan M. Spoor bought 22,026 shares of the stock in a transaction that occurred on Friday, March 28th. The stock was bought at an average price of $2.24 per share, with a total value of $49,338.24. Following the completion of the acquisition, the chief executive officer now owns 59,383 shares of the company’s stock, valued at $133,017.92. This trade represents a 58.96 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 115,696 shares of company stock valued at $256,344 in the last ninety days. Corporate insiders own 3.52% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CATX. Charles Schwab Investment Management Inc. grew its stake in Perspective Therapeutics by 221.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock worth $5,788,000 after buying an additional 298,778 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Perspective Therapeutics by 8.9% in the third quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock worth $274,000 after acquiring an additional 1,672 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of Perspective Therapeutics by 1,302.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company’s stock valued at $635,000 after purchasing an additional 44,174 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Perspective Therapeutics during the 3rd quarter valued at approximately $152,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Perspective Therapeutics by 5.8% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company’s stock worth $783,000 after acquiring an additional 3,211 shares in the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.